On July 28^th in South Africa, more than 100 members of the TB research community marched under the Louder than TB banner in the Walk the Talk event to raise awareness for TB and TB research.

SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered by 93 countries in the three years since introduction of the products.¹ The new medicines, which were first introduced nationally in Kenya in September 2016, are easier for caregivers to administer and for children to take. The announcement took place at the first International Global Health Security Conference in Sydney.

Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen.

GENEVA  (May 22, 2019) - This week at the Seventy-second World Health Assembly, TB Alliance is joining our partners in global health and product development to urge increased global funding and action to eradicate tuberculosis (TB). Today, delegates are assessing progress made since last year’s UN High Level Meeting (HLM) on TB as well as the 2017 HLM on Antimicrobial Resistance (AMR).

NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center of Excellence in Translational Research (CETR) grant (U19AI142735) for tuberculosis (TB) drug development. New translational research to develop novel anti-TB medicines is being carried out with partners at the University of Illinois at Chicago, Harvard University, Johns Hopkins University, and Research Triangle Institute.

NEW YORK, HERTFORDSHIRE, England and PITTSBURGH – April 18, 2019 – Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).

NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for the use of pretomanid as part of a new regimen, in combination with bedaquiline and linezolid, for the treatment of extensively drug-resistant (XDR) TB, treatment intolerant multidrug-resistant (MDR) TB, and treatment non-responsive MDR-TB.

Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments

[November 28, 2018, WASHINGTON, D.C.] – TB Alliance and partners were honored today as the winner of the Global Health Technologies Coalition (GHTC) 2018 Innovating for Impact Partnership Award, for the development of improved child-friendly tuberculosis (TB) medicines. Since the improved medicines were introduced in 2016, 85 countries have procured more than 800,000 treatment courses. Appropriately-dosed and palatable, these new medicines are improving TB treatment and survival for the estimated one million children stricken with TB each year.

[October 24, 2018, NEW YORK] - TB Alliance has joined the Innovative Medicines Initiative (IMI) as an Associated Partner on programs focused on antimicrobial resistance and innovation in clinical trials. IMI is a public-private partnership between the European Union and the European pharmaceutical industry that facilitates the development of medicines, especially in areas of unmet medical need including tuberculosis (TB).